RBC Capital Reiterates Outperform on Viridian Therapeutics, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has reiterated an Outperform rating on Viridian Therapeutics (NASDAQ:VRDN) and maintained a price target of $35.
August 28, 2024 | 12:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating for Viridian Therapeutics, maintaining a price target of $35, indicating confidence in the company's potential.
The reiteration of an Outperform rating and maintenance of a $35 price target by RBC Capital suggests a positive outlook for Viridian Therapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100